These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 4067428)

  • 21. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
    Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of obesity on the metabolism of apolipoprotein B in humans.
    Egusa G; Beltz WF; Grundy SM; Howard BV
    J Clin Invest; 1985 Aug; 76(2):596-603. PubMed ID: 4031064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modification of VLDL apoprotein B by acetaldehyde alters apoprotein B metabolism.
    Kervinen K; Hörkkö S; Beltz WF; Kesäniemi A
    Alcohol; 1995; 12(3):189-94. PubMed ID: 7639949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolism of very low density and intermediate density lipoproteins in patients with familial hypercholesterolaemia.
    Soutar AK; Myant NB; Thompson GR
    Atherosclerosis; 1982 Jun; 43(2-3):217-31. PubMed ID: 7115461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.
    Taskinen MR; Packard CJ; Shepherd J
    Diabetes; 1990 Sep; 39(9):1017-27. PubMed ID: 2200727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
    Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
    J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
    Packard CJ; Demant T; Stewart JP; Bedford D; Caslake MJ; Schwertfeger G; Bedynek A; Shepherd J; Seidel D
    J Lipid Res; 2000 Feb; 41(2):305-18. PubMed ID: 10681415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperbetalipoproteinemia with small low-density lipoprotein, a characteristic disorder of lipoprotein in essential hypertension.
    Ikeda K; Suzuki M; Ikebuchi M; Hara Y; Tsushima M; Yamamoto A; Harano Y
    J Diabetes Complications; 1995; 9(4):227-9. PubMed ID: 8573733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
    Vergès B; Florentin E; Baillot-Rudoni S; Monier S; Petit JM; Rageot D; Gambert P; Duvillard L
    Diabetologia; 2008 Aug; 51(8):1382-90. PubMed ID: 18535816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.
    Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y
    Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia.
    Demant T; Gaw A; Watts GF; Durrington P; Buckley B; Imrie CW; Wilson C; Packard CJ; Shepherd J
    J Lipid Res; 1993 Jan; 34(1):147-56. PubMed ID: 8445339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compensatory mechanisms governing the concentration of plasma low density lipoprotein.
    Howard BV; Egusa G; Beltz WF; Kesäniemi YA; Grundy SM
    J Lipid Res; 1986 Jan; 27(1):11-20. PubMed ID: 3958608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mevinolin and cholestyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein B in miniature pigs.
    Huff MW; Telford DE; Woodcroft K; Strong WL
    J Lipid Res; 1985 Oct; 26(10):1175-86. PubMed ID: 3906004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations.
    Ooi EM; Russell BS; Olson E; Sun SZ; Diffenderfer MR; Lichtenstein AH; Keilson L; Barrett PH; Schaefer EJ; Sprecher DL
    Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):459-66. PubMed ID: 22095987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.